Biotech · Private company
Infinity Pharmaceuticals, Inc.
Track this companyFree. Adds Infinity Pharmaceuticals, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials40 recruiting or active
Pipeline programs8From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline8
- AtezolizumabPhase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- BevacizumabPhase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- IPI-549 (eganelisib)Phase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- IPI-549 (eganelisib)Phase 2 · Bladder CancerClinicalTrials.gov · fetched Nov 12, 2026
- nab-paclitaxelPhase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- NivolumabPhase 2 · Bladder CancerClinicalTrials.gov · fetched Nov 12, 2026
- IPI-549 (eganelisib)Phase 1 · Advanced Solid Tumors (Part A/B/C/D)ClinicalTrials.gov · fetched Nov 12, 2026
- NivolumabPhase 1 · Advanced Solid Tumors (Part A/B/C/D)ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell CarcinomaPHASE2 · UNKNOWN · started Dec 17, 2019ClinicalTrials.gov NCT03961698 · fetched Nov 12, 2026
- Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)PHASE2 · COMPLETED · started Sep 25, 2019ClinicalTrials.gov NCT03980041 · fetched Nov 12, 2026
- A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic MalignanciesPHASE1 · COMPLETED · started Oct 15, 2018ClinicalTrials.gov NCT03719326 · fetched Nov 12, 2026
- A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549PHASE1 · UNKNOWN · started Dec 1, 2015ClinicalTrials.gov NCT02637531 · fetched Nov 12, 2026